Actively Recruiting
Randomized Study Comparing Bria-IMT Regimen with Checkpoint Inhibitor Versus Physicians Choice in Advanced Metastatic Breast Cancer
Led by BriaCell Therapeutics Corporation · Updated on 2026-09-02
404
Participants Needed
79
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating overall survival in patients with advanced metastatic or locally recurrent breast cancer who have no approved alternative therapies available. This Phase 3, multicenter, randomized, open-label study compares the Bria-IMT regimen combined with the checkpoint inhibitor Retifanlimab against treatment chosen by patients or physicians, known as Treatment of Physicians Choice TPC. The study also investigates the activity of the Bria-IMT regimen alone compared to its combination with Retifanlimab. Participants are initially randomized into three groups Bria-IMT regimen plus Retifanlimab combination therapy, TPC, and Bria-IMT regimen alone monotherapy. After enrolling the first 150 patients, the monotherapy group will be discontinued, and those patients may switch to combination therapy. The Bria-IMT regimen includes cyclophosphamide administered 2-3 days before SV-BR-1-GM given intradermally in four inoculations, followed by checkpoint inhibitor infusion plus interferon injections at inoculation sites over three days. Treatment cycles repeat every three weeks, while TPC is given per standard care at each site. Imaging assessments are conducted every six weeks twice, then every eight weeks thereafter unless disease progression or safety issues occur. During the study, participants will have regular therapy cycles and imaging assessments to monitor disease progression. Researchers will evaluate outcomes such as overall survival up to 60 months, progression-free survival, clinical benefit rate, overall response rate, quality of life, and central nervous system event-free survival. Safety and treatment effects will be closely monitored throughout the trial, which is expected to complete by June 2028.
CONDITIONS
Brief Title
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Research Team
M
Malobika Bhowmick
M
Marcela Salgado, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here